News
GENFF
0.039
NaN%
--
Genflow Biosciences PLC Announces Corporate Update
Barchart · 10/09 08:10
Genflow Biosciences PLC Announces Presentation of Interim Results
Barchart · 10/05 01:40
Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity
Barchart · 09/29 08:32
Genflow Biosciences GAAP EPS of -£0.08
Seeking Alpha · 09/29 08:08
Genflow Biosciences PLC Announces Half-year Financial Report
Barchart · 09/29 01:00
Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met
Barchart · 09/08 01:00
Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser
Barchart · 09/07 01:00
Genflow Biosciences PLC Announces Patent Update
Barchart · 08/03 01:00
Genflow Biosciences PLC Announces Mid-Year Operational and Corporate Summary
Barchart · 07/13 01:00
Genflow Biosciences PLC Announces Result of AGM
Barchart · 06/29 06:35
Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026
Barchart · 06/17 01:00
More
Webull provides a variety of real-time GENFF stock news. You can receive the latest news about Genflow Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About GENFF
Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product pipeline includes GF-1002, GF-1003, GF-1004, GF-1005 and GF-1006. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-1004 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-1003 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.